What is Juno Bio?
Juno Bio operates at the intersection of biotechnology and consumer health, providing an at-home vaginal microbiome testing service. The company's platform simplifies the diagnostic process, allowing individuals to collect samples conveniently while receiving comprehensive, actionable insights into their vaginal health. Beyond mere testing, Juno Bio distinguishes itself by integrating personalized consultations with vaginal coaches, fostering a supportive and non-judgmental environment for users. By focusing on the often-overlooked area of vaginal health, the company is actively working to bridge the gender health gap, providing a standard of care that is both accessible and scientifically rigorous. Their commitment to research and data-driven health outcomes positions them as a pivotal player in the evolving landscape of personalized medicine and reproductive health technology.
How much funding has Juno Bio raised?
Juno Bio has raised a total of $3.8M across 1 funding round:
Other Financing Round
$3.8M
Other Financing Round (2026): $3.8M with participation from Artesian, Entrepreneur First, Ada Ventures, and ILLUMINA
Key Investors in Juno Bio
Artesian
Artesian is a global alternative investment management firm specializing in public and private debt, venture capital, and impact investment strategies.
Entrepreneur First
Entrepreneur First is an international talent investor that supports individuals in building technology companies from the ground up.
Ada Ventures
Ada Ventures is a pre-seed inclusive venture capital firm that invests in European founders building technology companies focused on climate equity, economic empowerment, and healthy aging.
What's next for Juno Bio?
With this major enterprise-level funding, Juno Bio is poised to accelerate its growth trajectory and expand its research capabilities. The strategic allocation of this capital will likely focus on enhancing the company's diagnostic technology, scaling its service delivery model, and broadening its reach to underserved populations. As the company continues to refine its microbiome testing protocols, it is expected to deepen its impact on clinical outcomes, potentially influencing broader standards in gynecological care. The involvement of high-profile investors suggests a long-term commitment to scaling Juno Bio's infrastructure, ensuring that the company remains at the forefront of the femtech sector as it transitions into its next phase of market expansion and product development.
See full Juno Bio company page
